<DOC>
	<DOCNO>NCT00884845</DOCNO>
	<brief_summary>Phase I multicenter , open-label , dose-escalating clinical pharmacokinetic trial PM02734 administer combination erlotinib determine safety tolerability identify dose limit toxicity ( DLT ) recommend dose ( RD ) combination PM02734 erlotinib , patient advance malignant solid tumor .</brief_summary>
	<brief_title>Trial PM02734 Administered Combination With Erlotinib Patients With Advanced Malignant Solid Tumors</brief_title>
	<detailed_description>Phase I multicenter , open-label , dose-escalating clinical pharmacokinetic trial PM02734 administer combination erlotinib determine safety tolerability identify dose limit toxicity ( DLT ) recommend dose ( RD ) combination PM02734 erlotinib , determine preliminary pharmacokinetics ( PK ) combination , evaluate preliminary PK/pharmacodynamic correlation , evaluate preliminary antitumor activity , perform preliminary pharmacogenomic ( PGx ) study explore molecular predictor response ErbB receptor antagonist PM02734 patient advance malignant solid tumor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Voluntary write informed consent form . Histologically cytologically confirm advanced malignant solid tumor . Measurable nonmeasurable disease follow ( RECIST ) Age ≥ 18 year . Life expectancy ≥ 3 month . Performance status ECOG ≤ 2 . Recovery drugrelated adverse event ( AEs ) derive previous treatment . Appropriate bone marrow , liver renal function . Left ventricular ejection fraction ( LVEF ) within normal limit institution . Women childbearing potential must negative serum pregnancy test study entry . Both men woman must agree use medically acceptable method contraception throughout treatment period three month discontinuation treatment . Prior therapy PM02734 . Pregnant lactate woman . Less four week radiation therapy . Evidence progressive central nervous system ( CNS ) metastases . symptomatic brain leptomeningeal metastasis . Other relevant disease adverse clinical condition . Any major illness , Investigator 's judgment . Limitation patient 's ability comply treatment followup participate protocol . Ingestion potent cytochrome CYP3A4 inhibitor . Treatment investigational product 30day period prior first infusion . Known hypersensitivity component PM02734 erlotinib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>PM2734</keyword>
	<keyword>Tumors</keyword>
	<keyword>PharmaMar</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
</DOC>